Welichem Biotech Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Welichem Biotech Inc.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.
How To Make A Global First-In-Class Drug In China
The story so far of how an aspiring Western returnee researcher became a fully charged pharma entrepreneur in China’s wild world of drug innovation.
IN VIVO: Deals Shaping The Medical Industry, May 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
Biopharma Quarterly Deal Statistics, Q2 2012
Follow-on public offerings continued to dominate, with 19 transactions making up almost half of Q2’s $2.7 billion financing volume. M&A dollars, up nearly four times that of Q1, totaled $34.7 billion, for 28 completed transactions, seven of which topped the billion dollar mark. In alliances, the Q2 potential deal value – also largely increased over the previous quarter’s – marked possibly the highest amount ever seen along with maybe the most expensive deal ever: Walgreen $6.6 billion agreement to purchase a minority equity share in Alliance Boots, bringing in over half of Q2’s value.
- Topical Delivery
- Drug Delivery
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.